Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SWE-NEO: Swedish NeoAdjuvant Trial Comparing Anti-PD-1 Monotherapy to Combined Anti-CTLA-4/Anti-PD-1 Blockade in Resectable Stage III Melanoma

NCT06794775 is registered in ClinicalTrials.gov with Hildur Helgadottir as lead sponsor.

NCT NCT06794775
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06794775 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SWE-NEO: Swedish NeoAdjuvant Trial Comparing Anti-PD-1 Monotherapy to Combined Anti-CTLA-4/Anti-PD-1 Blockade in Resectable Stage III Melanoma
Lead sponsor
Hildur Helgadottir
Phase
Phase 3
Overall status
Recruiting
Start date
July 10, 2025
Completion date
April 15, 2032
Enrollment
128 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

malignant melanoma stage iii